Abbott's FreeStyle Libre glucose monitoring system approved in Australia

Abbott ($ABT) announced that it has received Australian approval for its FreeStyle Libre Flash Glucose Monitoring System, which eliminates the need for routine finger pricks. "We know through our research that pain, inconvenience and indiscretion of finger pricking were the key reasons people with diabetes aren't managing their diabetes as well as they should," said Abbott's senior vice president of diabetes care, Jared Watkin. "Addressing these concerns has guided the development of FreeStyle Libre--a transformational product designed to not only remove the pain of routine finger pricking but also seamlessly integrate into daily lives--empowering people with diabetes to make better-informed treatment decisions and live their best lives through better health." Release

Suggested Articles

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.

President Emmanuel Ligner talks about finalizing a multibillion-dollar deal while adjusting and responding to the global COVID-19 crisis.